{"schema_version":"secwatch.filing_event.v1","accession":"0001635088-26-000009","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2026-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.700371+00:00","generated_at":"2026-05-16T04:06:01.394653+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant reports positive Phase 2 brepocitinib data in CS; Q3 loss $313.7M vs $208.9M","bullets":["Phase 2 BEACON study: brepocitinib 45mg achieved 22.3-point CSAMI-A improvement vs 0.7 placebo (Δ21.6, p<0.0001).","NDA submitted to FDA for brepocitinib in dermatomyositis; Phase 3 CS study planned for 2026.","Q3 loss from continuing ops $313.7M ($0.38/share) vs $208.9M ($0.22); revenue fell to $2M from $9M.","Cash and marketable securities of $4.5B as of Dec 31, 2025; R&D expenses rose to $165.4M.","Immunovant's IMVT-1402 D2T RA trial fully enrolled; Genevant jury trial set for Mar 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001635088-26-000009","json":"https://secwatch.observer/filing/0001635088-26-000009.json","markdown":"https://secwatch.observer/filing/0001635088-26-000009.md","text":"https://secwatch.observer/filing/0001635088-26-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/0001635088-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/roiv-20260206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:06:01.394653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}